Phase I trial of molecular targeted therapy with adoptive cell therapy for DIPG and neuroblastoma Aug. 27, 2021
Phase I study evaluates PGV-001-based personalized multipeptide vaccines for prostate cancer Aug. 27, 2021
New phase I/II trial investigates RVU-120 in relapsed/refractory metastatic or advanced solid tumors Aug. 26, 2021
HUTCHMED begins phase Ib/II study of fruquintinib with tislelizumab in TNBC and endometrial cancer Aug. 26, 2021
RSS